Volume | 150,258 |
|
|||||
News | - | ||||||
Day High | 1.58 | Low High |
|||||
Day Low | 1.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
InflaRx NV | IFRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.55 | 1.50 | 1.58 | 1.50 | 1.58 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
674 | 150,258 | $ 1.54 | $ 231,634 | - | 1.14 - 7.2499 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:37 | formt | 779 | $ 1.52 | USD |
InflaRx NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
81.71M | 54.12M | - | 20.16M | -29.48M | -0.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
InflaRx NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.61 | 1.72 | 1.48 | 1.58 | 115,110 | -0.09 | -5.59% |
1 Month | 1.53 | 1.92 | 1.40 | 1.64 | 238,916 | -0.01 | -0.65% |
3 Months | 1.75 | 2.11 | 1.40 | 1.69 | 245,824 | -0.23 | -13.14% |
6 Months | 3.77 | 3.77 | 1.14 | 1.65 | 309,438 | -2.25 | -59.68% |
1 Year | 1.69 | 7.2499 | 1.14 | 4.64 | 820,526 | -0.17 | -10.06% |
3 Years | 4.65 | 7.2499 | 0.7762 | 3.95 | 669,373 | -3.13 | -67.31% |
5 Years | 47.78 | 53.10 | 0.7762 | 4.70 | 707,894 | -46.26 | -96.82% |
InflaRx NV Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |